{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adeno-Associated+Virus+%28AAV%29",
    "query": {
      "condition": "Adeno-Associated Virus (AAV)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 57,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adeno-Associated+Virus+%28AAV%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:01:22.452Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06333249",
      "title": "A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "X-Linked Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "rAAV2tYF-GRK1-RPGR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Beacon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "8 Years to 50 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2021-04-13",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 6,
      "location_summary": "Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333249"
    },
    {
      "nct_id": "NCT00377416",
      "title": "Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "rAAV2-CB-hAAT Gene Vector",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2004-03",
      "completion_date": "2020-01",
      "has_results": false,
      "last_update_posted_date": "2020-04-10",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Worcester, Massachusetts",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377416"
    },
    {
      "nct_id": "NCT00430768",
      "title": "Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "rAAV1-CB-hAAT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2006-02",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Worcester, Massachusetts",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00430768"
    },
    {
      "nct_id": "NCT05345171",
      "title": "Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "OTC Deficiency"
      ],
      "interventions": [
        {
          "name": "DTX301",
          "type": "GENETIC"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Oral Corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "Placebo for oral corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "Sodium Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2022-10-18",
      "completion_date": "2031-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05345171"
    },
    {
      "nct_id": "NCT00516477",
      "title": "Safety Study in Subjects With Leber Congenital Amaurosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leber Congenital Amaurosis"
      ],
      "interventions": [
        {
          "name": "voretigene neparvovec-rzyl",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-09",
      "completion_date": "2018-03-20",
      "has_results": false,
      "last_update_posted_date": "2020-11-02",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516477"
    },
    {
      "nct_id": "NCT03588299",
      "title": "Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a \"Shuttle\"",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAY2599023 (DTX201)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2018-11-07",
      "completion_date": "2026-11-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03588299"
    },
    {
      "nct_id": "NCT00087789",
      "title": "CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CERE-110: Adeno-Associated Virus Delivery of NGF",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2004-06",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2022-11-10",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Chicago, Illinois",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087789"
    },
    {
      "nct_id": "NCT00494195",
      "title": "Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscular Dystrophies"
      ],
      "interventions": [
        {
          "name": "rAAV1.tMCK.human-alpha-sarcoglycan- First cohort",
          "type": "GENETIC"
        },
        {
          "name": "Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2008-03",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00494195"
    },
    {
      "nct_id": "NCT02416622",
      "title": "Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "X-linked Retinoschisis"
      ],
      "interventions": [
        {
          "name": "rAAV2tYF-CB-hRS1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Beacon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "6 Years and older · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2015-05",
      "completion_date": "2023-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Miami, Florida • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02416622"
    },
    {
      "nct_id": "NCT00428935",
      "title": "Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "rAAV2.5-CMV-minidystrophin (d3990)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "15 Years",
        "sex": "MALE",
        "summary": "5 Years to 15 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2006-03",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-05-22T04:01:22.452Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428935"
    }
  ]
}